About AiCuris
AiCuris is a company based in Wuppertal (Germany) founded in 2006 was acquired by Asahi Kasei in February 2026.. AiCuris has raised $74.8 million across 4 funding rounds from investors including Asahi Kasei. The company has 61 employees as of December 31, 2020. AiCuris offers products and services including AIC468 and Pipeline Products. AiCuris operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others.
- Headquarter Wuppertal, Germany
- Employees 61 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aicuris Anti-Infective Cures Gmbh
-
Annual Revenue
$69.77 M (USD)-48as on Dec 31, 2018
-
Net Profit
$10.06 M (USD)-74as on Dec 31, 2019
-
EBITDA
$10.06 M (USD)-74as on Dec 31, 2019
-
Total Equity Funding
$74.8 M (USD)
in 4 rounds
-
Latest Funding Round
- Investors
-
Employee Count
61
as on Dec 31, 2020
-
Acquired by
Asahi Kasei
(Feb 26, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of AiCuris
AiCuris offers a comprehensive portfolio of products and services, including AIC468 and Pipeline Products. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets BK Virus infections in kidney transplant recipients.
Advances anti-viral therapies for immunocompromised patients.
Funding Insights of AiCuris
AiCuris has successfully raised a total of $74.8M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Last Round
-
First Round
First Round
(14 Apr 2010)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2017 | Amount | Grant - AiCuris | Valuation |
investors |
|
| Jan, 2017 | Amount | Grant - AiCuris | Valuation |
investors |
|
| Mar, 2015 | Amount | Grant - AiCuris | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in AiCuris
AiCuris has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Asahi Kasei. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
CDMO focused on manufacturing of liquid, solid & injectable drug formulations
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by AiCuris
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - AiCuris
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aicuris Comparisons
Competitors of AiCuris
AiCuris operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Brii Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| domain | founded_year | HQ Location |
Developer of biologics to treat hepatitis B infection
|
|
| domain | founded_year | HQ Location |
Developer of computationally designed VLP vaccines for treating multiple infections
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aicuris
Frequently Asked Questions about AiCuris
When was AiCuris founded?
AiCuris was founded in 2006 and raised its 1st funding round 4 years after it was founded.
Where is AiCuris located?
AiCuris is headquartered in Wuppertal, Germany. It is registered at Wuppertal, North Rhine-westphalia, Germany.
Who is the current CEO of AiCuris?
Holger Zimmermann is the current CEO of AiCuris.
Is AiCuris a funded company?
AiCuris is a funded company, having raised a total of $74.8M across 4 funding rounds to date. The company's 1st funding round was a Grant of $278.11K, raised on Apr 14, 2010.
How many employees does AiCuris have?
As of Dec 31, 2020, the latest employee count at AiCuris is 61.
What is the annual revenue of AiCuris?
Annual revenue of AiCuris is $69.77M as on Dec 31, 2018.
What does AiCuris do?
AiCuris was established in 2006 in Wuppertal, Germany, as a pharmaceutical firm focused on antiviral and antibacterial agents targeting life-threatening infections. Therapeutics in the pipeline include Prevymis (AIC246), a quinazoline-based CMV terminase inhibitor approved for human cytomegalovirus treatment; AIC316, advanced to phase II for herpes simplex; and AIC649, in phase I for hepatitis B virus. Operations center on drug development for unmet needs in infectious diseases.
Who are the top competitors of AiCuris?
AiCuris's top competitors include Moderna, Adaptive Biotechnologies and Generate Biomedicines.
What products or services does AiCuris offer?
AiCuris offers AIC468 and Pipeline Products.
Who are AiCuris's investors?
AiCuris has 1 investor. Key investors include Asahi Kasei.